Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ProspeCtive Observational Real-world Study of uBRogepant and Atogepant in Israel (COBRA)

NCT05827887 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05827887
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05827887 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ProspeCtive Observational Real-world Study of uBRogepant and Atogepant in Israel (COBRA)
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
June 25, 2023
Completion date
January 28, 2026
Enrollment
226 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

migraine